Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

ced 2008 mipomersen development plan with Genzyme

-- Reported preclinical study in Circulation showing that mipomersen

lowers Lp(a) and oxidized-LDL, independent risk factors for

cardiovascular disease

-- Initiated Phase 3 study in heterozygous FH subjects with coronary

artery disease

-- Granted broad patent coverage for antisense compounds targeting

apolipoprotein B, U.S. Patent No. 7,407,943 entitled "Antisense

modulation of Apolipoprotein B Expression"

Metabolic Program

-- Highlighted our robust diabetes and obesity portfolio with nine

presentations and posters at the American Diabetes Association meeting

-- Presented new preclinical data relating to ISIS 388626, Isis' drug

targeting SGLT2

-- Presented results from eight research programs on novel targets

that offer new mechanisms to address metabolic diseases, including

obesity

Other Partnered Programs

-- ATL and Teva reported encouraging Phase 2 results for ATL/TV1102,

targeting VLA-4 in patients with multiple sclerosis

-- Partnered oncology drugs highlighted at the American Society of

Clinical Oncology demonstrate the potential of antisense technology to

treat multiple cancers

-- OncoGenex reported encouraging Phase 2 results on OGX-011,

targeting clusterin, in patients with hormone refractory prostate

cancer

-- Eli Lilly and Company reported positive Phase 1 clinical trial

results for LY2181308, targeting survivin

-- Atlantic Healthcare received U.S. orphan drug designation for

alicaforsen for the treatment of pouchitis

-- Altair Therapeutics advanced AIR 645 into Phase 1 studies for the

treatment of asthma

Regulus Therapeutics (microRNA Joint Venture)

-- Entered into strategic alliance wit
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... be used for detailed studies of what happens on ... pharmaceuticals research, among other applications. A group of researchers ... artificial cell membranes form across a large number of ... between the interior of a cell and its surroundings ... a surface layer that holds the cell together and ...
(Date:9/2/2014)... 2014 Persistence Market Research ( ... Pharmaceutical, Biopharma and Life Sciences: North America ... membrane technology market for pharmaceutical, biopharma and life sciences is ... expected to grow at a CAGR of 9.1% from ... USD 10,886.0 million in 2019. Browse the ...
(Date:9/2/2014)... Myriant Corporation, a global renewable chemicals ... agreement with Azelis Group, a specialty chemicals distribution ... in the Nordics, Benelux, France, Iberia, Italy, the ... industrial and base chemicals markets. , “As a ... chemical portfolio with extensive distribution networks providing Myriant ...
(Date:9/2/2014)... Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... announced the appointment of Debra Zack , ... appointment of Lloyd Rowland , senior vice ... "Debra,s expertise in biologics clinical development ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... Dr. ... San Antonio and South Central Texas, , ... (PRWEB) June 15, 2010 -- For those looking for a trimmer physique without ... Zeltiq ™ Procedure, a new non-invasive body contouring procedure, at his practice - Advanced ...
... data from a retrospective cohort study showed that up to three quarters ... have a substantial adverse effect on major PD-related clinical and health economic ... Disease and Movement Disorders in Buenos Aires, Argentina ( June ... , "The ...
... leading publication on diversity and business, has recognized University Hospitals as a leader among ... , , ... Companies for Diversity based on results from an extensive questionnaire. This is the first ... , , ...
Cached Biology Technology:Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction 2Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 2New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 4Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation 2
(Date:9/2/2014)... perching birds, that migrate by night tend to fly ... reach their destinations. This seasonal difference in flight speed ... migratory flights, says researcher Cecilia Nilsson of Lund University ... Sociobiology . , Nilsson, in a group led ... measure over three years the speed by which birds ...
(Date:9/2/2014)... 2, 2014 Best-selling author Sam Kean stops by ... Megalodon, the 50-foot super shark that, despite what "Shark ... Learn all about it at http://youtu.be/KhFygIoW_MA . , ... of Madness, Love and the History of the World ... the Reactions treatment in a 10-episode video series produced ...
(Date:9/2/2014)... lithographic limestone is well known as a result ... area (for example, Archaeopteryx). Now, for the first ... French equivalent of these outcrops - discoveries which ... water treader. , Despite the abundance of fossils ... been obtained from the Late Kimmeridgian equivalents of ...
Breaking Biology News(10 mins):Migrating birds sprint in spring, but take things easy in autumn 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... Research to be presented at the Annual Meeting of the ... society for research into all aspects of eating and drinking ... their pregnancy were at risk to develop obesity and type ... that both prenatal stress exposure and passive stress coping style ...
... make a person more susceptible to the lung infection ... , the online open-access journal of the American Society ... (METH) significantly enhanced colonization of the lungs by ... and the time to death in mouse models. ...
... mind that is, your happiness affects your genes, ... from UCLA,s Cousins Center for Psychoneuroimmunology and the University of ... What they found is that different types ... People who have high levels of what ...
Cached Biology News:Methamphetamine increases susceptibility to deadly fungal infection 2Methamphetamine increases susceptibility to deadly fungal infection 3Be happy: Your genes may thank you for it 2Be happy: Your genes may thank you for it 3
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Biology Products: